LVGN 8325
Alternative Names: LVGN-8325Latest Information Update: 07 Jan 2022
At a glance
- Originator Lyvgen Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action CD40 antigen stimulants; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Jan 2022 LVGN 8325 is available for licensing as of 05 Jan 2022. https://www.lyvgen.com
- 05 Jan 2022 Preclinical trials in Solid tumours in China (Parenteral) as of January 2022 (Lyvgen Biopharma pipeline; January 2022)